MX2024008691A - Composiciones y metodos de triptamina. - Google Patents

Composiciones y metodos de triptamina.

Info

Publication number
MX2024008691A
MX2024008691A MX2024008691A MX2024008691A MX2024008691A MX 2024008691 A MX2024008691 A MX 2024008691A MX 2024008691 A MX2024008691 A MX 2024008691A MX 2024008691 A MX2024008691 A MX 2024008691A MX 2024008691 A MX2024008691 A MX 2024008691A
Authority
MX
Mexico
Prior art keywords
sub
methods
salt forms
disorders
tryptamine
Prior art date
Application number
MX2024008691A
Other languages
English (en)
Spanish (es)
Inventor
Pradip M Pathare
Alex Nivorozhkin
Kenneth L Avery
James He Huang
Mohammed I Shukoor
Original Assignee
Cybin Irl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybin Irl Ltd filed Critical Cybin Irl Ltd
Publication of MX2024008691A publication Critical patent/MX2024008691A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2024008691A 2022-01-14 2023-01-13 Composiciones y metodos de triptamina. MX2024008691A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263299599P 2022-01-14 2022-01-14
US202263384704P 2022-11-22 2022-11-22
PCT/EP2023/050702 WO2023135237A1 (en) 2022-01-14 2023-01-13 Tryptamine compositions and methods

Publications (1)

Publication Number Publication Date
MX2024008691A true MX2024008691A (es) 2024-07-19

Family

ID=85018123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008691A MX2024008691A (es) 2022-01-14 2023-01-13 Composiciones y metodos de triptamina.

Country Status (9)

Country Link
US (1) US20250051279A1 (enExample)
EP (1) EP4463440A1 (enExample)
JP (1) JP2025502208A (enExample)
KR (1) KR20240134951A (enExample)
AU (1) AU2023207801B2 (enExample)
CA (1) CA3259235A1 (enExample)
IL (1) IL313889A (enExample)
MX (1) MX2024008691A (enExample)
WO (1) WO2023135237A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
TW202617141A (zh) 2024-07-10 2026-05-01 英商賽本英國有限公司 包含氘化n,n-二甲基色胺之醫藥組合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US6488648B1 (en) 1999-01-14 2002-12-03 Teijin Limited Device for feeding a powder in a predetermined amount and method thereof
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
AU2002340083A1 (en) 2001-09-28 2003-04-07 Kurve Technology, Inc Nasal nebulizer
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US7267121B2 (en) 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
IL312785B2 (en) * 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) * 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) * 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
RU199823U1 (ru) 2020-06-10 2020-09-21 Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий Устройство для лечения бронхолегочных заболеваний
EP4221682A2 (en) * 2020-10-02 2023-08-09 Cybin IRL Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
EP4031529B1 (en) * 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
MX2023010317A (es) * 2021-03-02 2023-11-09 Mindset Pharma Inc Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
AU2022342266B2 (en) * 2021-09-08 2026-03-26 Cybin Irl Limited Combination drug therapies

Also Published As

Publication number Publication date
WO2023135237A1 (en) 2023-07-20
EP4463440A1 (en) 2024-11-20
JP2025502208A (ja) 2025-01-24
US20250051279A1 (en) 2025-02-13
CA3259235A1 (en) 2023-07-20
KR20240134951A (ko) 2024-09-10
IL313889A (en) 2024-08-01
AU2023207801A1 (en) 2024-06-27
AU2023207801B2 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
IS7891A (is) Skiptitengd þrísýklísk gamma-karbólín sem serótónín viðtaka gerandefni og mótverkunarefni
WO2000010551A3 (en) Methods of using and compositions comprising dopamine reuptake inhibitors
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
SI1678172T1 (sl) AzabicikliŽŤne spojine za lajšanje boleŽŤine in zdravljenje motenj centralnega ĹľivŽŤnega sistema
MX2023014630A (es) Activadores de dimetoxifenilalquilamina de receptores de serotonina.
PH12021551449A1 (en) Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
MX2024011170A (es) Compuestos organicos.
RU2006105782A (ru) Производные 1-сульфонилиндола, их получение и их применение в качестве лигандов 5-нт-6
EA201992127A1 (ru) ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ АЛИЦИКЛИЧЕСКИ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА
JPH08183735A (ja) 不安症の治療
WO2002004456A1 (en) SUBSTITUTED 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINO[4,5-b]PYRANO[3,2-e]INDOLES
ZA202404599B (en) Heteroalicyclic derivatives and their use in the treatment of cns disorders
KR20010032009A (ko) 수면성 무호흡의 치료에 미타자핀을 사용하는 방법
EP1007046A1 (en) 1h-indole-3-glyoxylamides for the treatment of chronic bronchitis
MX2023009285A (es) Compuestos novedosos.
JPH11501051A (ja) 強迫性障害、睡眠時無呼吸、性的機能障害、嘔吐および乗物酔いの処置を意図する医薬
ES2815555T3 (es) Triple combinación de antagonistas del receptor 5-HT6 puros, inhibidores de la acetilcolinesterasa y antagonista del receptor NMDA
MX2025002007A (es) Compuestos heteroaromaticos para el tratamiento de trastornos neurologicos
KR20240134951A (ko) 트립타민 조성물 및 방법
MX2025008544A (es) Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo
JP2005513105A (ja) 臨床的うつ病を治療するためのデオキシペガニンの使用
ES2818898T3 (es) Combinación triple de agonistas inversos del receptor de histamina-3, inhibidores de la acetilcolinesterasa y antagonista del receptor de nmda
GEAP202416375A (en) Pro drugs of pde10 compounds
ES2810983T3 (es) Combinación de agonistas inversos del receptor de histamina-3 con inhibidores de acetilcolinesterasa
ZA202405718B (en) Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders